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Repulsive guidance molecule (RGM) is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein that has diverse
functions in the developing and pathological central nervous system (CNS). The binding of RGM to its receptor
neogenin regulates axon guidance, neuronal differentiation, and survival during the development of the CNS. In the
pathological state, RGM expression is induced after spinal cord injury, and the inhibition of RGM promotes axon
growth and functional recovery. Furthermore, RGM expression is also observed in immune cells, and RGM regulates
inflammation and neurodegeneration in autoimmune encephalomyelitis. RGMa induces T cell activation in
experimental autoimmune encephalomyelitis (EAE), which is the animal model of multiple sclerosis (MS). RGM is
expressed in pathogenic Th17 cells and induces neurodegeneration by binding to neogenin. Angiogenesis is an
additional key factor involved in the pathophysiology of EAE. Via neogenin, treatment with RGMa can suppress
endothelial tube formation; this finding indicates that RGMa inhibits neovascularization. These observations suggest
the feasibility of utilizing the RGMa-neogenin signaling pathway as a therapeutic target to overcome inflammation
and neurodegeneration. This review focuses on the molecular mechanisms of inflammation and angiogenesis via
RGM-neogenin signaling.
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Repulsive guidance molecule (RGM) is a glycosylpho-
sphatidylinositol (GPI)-anchored glycoprotein with an
N-terminal signal peptide, an Arg-Gly-Asp site, a partial
von Willebrand type D domain, and a hydrophobic do-
main of unknown function [1]. RGM was originally
identified as an axon repellent in the chick retinotectal
system [2, 3]. Neogenin, the receptor for RGM and
netrins, is widely expressed in both embryonic and adult
tissues and mediates various functions [4, 5]. There are
three homologs of RGM in vertebrates: RGMa, RGMb
(DRAGON), and RGMc (hemojuvelin). The homologies
of chick RGM to mouse RGMa, RGMb, and RGMc are
78, 43, and 40%, respectively.
The binding of RGMa to neogenin regulates axon
guidance, neuronal differentiation, and survival during
the development of the central nervous system (CNS)
[6–8]. Although RGMa expression levels are relatively* Correspondence: yuki-fujita@molneu.med.osaka-u.ac.jp;
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lowing ischemic stroke in humans and spinal cord injury
in rats [9, 10]. In an animal model of spinal cord injury,
treatment with an RGMa-neutralizing antibody at the
lesion site significantly enhances axon regeneration and
motor function recovery [11]. Because the stimulation of
neurons with RGMa induces RhoA and ROCK (Rho-as-
sociated coiled-coil-containing protein kinase), resulting
in axon growth inhibition, the effect of this antibody
may be dependent on the inhibition of this signaling
pathway.
In addition to its aforementioned roles, RGMa is in-
volved in neuroinflammatory diseases. The notion that
the pathogenesis of multiple sclerosis (MS) is associated
with acquired autoimmunity to the CNS has been widely
accepted. In MS, immune cells infiltrate the CNS and at-
tack myelin sheaths, leading to demyelination, axonal
damage, and neurological disabilities [12, 13]. CD4+ T
cells are critical effector cells in CNS inflammation [14].
Interestingly, the inhibition of RGMa via a neutralizing
antibody reduces cytokine production, demyelination,
and neurodegeneration and relieves neurological deficitsle is distributed under the terms of the Creative Commons Attribution 4.0
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[15, 16]. In addition to its role in neuroimmune interac-
tions, RGMa inhibits angiogenesis, which is often
accompanied by inflammation, as mentioned below.
Thus, these findings indicate that the RGM-neogenin
signaling pathway is strongly associated with disease se-
verity in neuroinflammatory diseases. In this review, we
introduce the pivotal role of RGMa in inflammation and
angiogenesis and discuss the potential therapeutic impli-
cations of targeting this signaling.
The RGMa-neogenin pathway mediates auto-
immune encephalomyelitis
Although the RGM-neogenin interaction mediates diverse
functions in the developing and adult CNS, we also found
that RGMa was expressed in bone marrow-derived den-
dritic cells and that neogenin was expressed in CD4+ T
cells. Based on these observations, we assessed the role of
RGMa in immune systems and found that the inhibition
of RGMa suppressed the T cell response and attenuated
the severity of EAE [15]. RGMa treatment of CD4+ T cells
induces the activation of the small GTPase Rap1 and
increases the adhesion of CD4+ T cells to intracellular ad-
hesion molecule-1 (ICAM-1). Treatment with an RGMa-
neutralizing antibody attenuates the clinical severity of
myelin oligodendrocyte glycoprotein (MOG)-induced
EAE and diminishes relapses in proteolipid protein (PLP)-
induced EAE. In humans, an RGMa-specific antibody
reduces T cell proliferation and pro-inflammatory cyto-
kine production in peripheral blood mononuclear cells
(PBMCs) from individuals with MS. Thus, the RGMa-
neogenin signaling pathway is involved in T cell-
mediated autoimmune processes in MS (Fig. 1).
Interferon-gamma (IFN-γ)-producing Th1 cells were
initially regarded as a predominant effector CD4+ T cell
subset that induces the pathogenesis of MS [17]. More
recently, interleukin-23 (IL-23) has been shown to beFig. 1 RGMa-neogenin signaling mediates autoimmune encephalomyelitis
to the activation of CD4+ T cells in both the peripheral and the central ner
immune responses and ameliorates the severity of EAErequired for the induction of EAE [18] and the patho-
genic activity of T helper type 17 (Th17) cells. The key
role of IL-17-producing Th17 cells in the pathogenesis
of EAE has been established [19]. Indeed, a deficiency of
IL-17, IL-17 receptor, or IL-23 receptor diminishes clin-
ical signs in EAE [20–22]. Interestingly, among T cell
subsets, including Th0, Th1, Th17, and Treg cells, Th17
cells highly express RGMa. The specific function of
RGMa in Th17 cells was determined to be involved in
neurodegeneration in EAE [16]. In particular, in Th17
cells, RGMa binds to neogenin and induces Akt
dephosphorylation and axonal degeneration (Fig. 2).
An RGMa-specific neutralizing antibody diminished
neuronal damage and alleviated clinical symptoms of
Th17-induced EAE. Taken together, these observations
suggest that RGMa could be a therapeutic target for
MS. Polymorphisms of RGMa have been correlated
with expression changes in IFN-γ and tumor necrosis
factor (TNF) in MS patients [23]. This finding raises
the intriguing possibility of an association between
genetic susceptibility in MS pathogenesis and RGMa.
Angiogenesis via the RGMa-neogenin pathway
In MS, in addition to various prominent features, such as
inflammation, demyelination, and axonal damage, neovas-
cularization is found in inflammatory lesions. In EAE, an
angiogenic response is observed following alterations in
blood-brain barrier (BBB) permeability and the release of
vascular endothelial growth factor (VEGF) [24, 25]. Both
detrimental and beneficial effects have been reported in
angiogenesis. Since the angiogenic response is related to
excess energy consumption and the expansion of inflam-
mation, this response’s pathological contributions to the
disease progression of MS and EAE are widely accepted
[26]. However, trophic factors from new vessels exert posi-
tive effects on the nervous systems. VEGF derived from
new blood vessels exhibits pro-inflammatory effects. RGMa in antigen-presenting cells (APCs) binds to neogenin, leading
vous systems. Blocking RGMa with a neutralizing antibody diminishes
Fig. 2 RGMa in Th17 cells induces neurodegeneration. RGMa is preferentially expressed in Th17 cells. The association of RGMa with neogenin in
neurons induces neurodegeneration through the dephosphorylation of Akt
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processes during the late phase of EAE. VEGF mediates
the proliferation, migration, and differentiation of neural
progenitors and the survival and migration of oligo-
dendrocyte precursor cells [27, 28]. Prostaglandin I2
(PGI2) produced from new blood vessels is associated with
motor recovery in EAE [29]. Thus, specific molecules de-
rived from new vascular cells can be therapeutic targets
for MS.
We have shown that RGMa inhibits angiogenesis via
neogenin [30]. In the presence of VEGF, RGMa sup-
presses endothelial tube formation by human umbilical
artery endothelial cells (HUAECs), and this effect could
be partially reversed by knocking down neogenin. RGMa
treatment of HUAECs decreased VEGF-induced phos-
phorylation of focal adhesion kinase (FAK). It has been
demonstrated that netrins, the other ligands of neogenin,
also regulate neovascularization. The binding of netrin-4
to neogenin causes neogenin to associate with its co-
receptor Unc5b and inhibits angiogenesis both in cul-
tured HUAECs and in an animal model of laser-induced
choroidal neovascularization [31]. In contrast, netrin-1
promotes tube formation in HUAECs, and knocking
down netrin-1 in zebrafish inhibits vascular sprouting,
suggesting that netrin-1 induces angiogenesis [32–34].
However, it is also reported that netrin-1 inhibits angio-
genesis via the activation of Unc5b and the disruption of
Unc5b induces excess vessel branching and the exten-
sion of endothelial filopodia [35, 36]. Netrin-4 binds only
to neogenin, whereas netrin-1 is predicted to interact
with neogenin, Unc5b, and Unc5c. Differences inbinding affinity to neogenin might be responsible for
these proteins’ different effects on angiogenesis.Conclusions
Here, we reviewed the role of RGMa in inflammation
and angiogenesis, particularly in MS. Since RGMa medi-
ates both immune responses and neurodegeneration in
EAE, the inhibition of RGMa could be a promising
therapeutic intervention for MS. Further research will
establish the feasibility of an anti-RGMa antibody for
treating MS.
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